Efficacy and safety of the Baypure Clearing Serum

A single-arm, open-label clinical study to evaluate the efficacy and safety of the Baypure Clearing Serum in improving skin pigmentation, dark spots, hydration, and overall skin Parameters - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/10/096411

Enrollment

Registered

2025-10-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Clearing Serum: Apply 5–6 drops applied topically on face and neck, twice daily. Duration: 28 days Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female, 18–45 years old 2. Visible pigmentation or dark spots 3. Willing to provide written informed consent 4. Women of childbearing potential must have a negative urine pregnancy test 5. Able and willing to comply with study procedures

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women 2. History of systemic or skin cancers within the last 5 years 3. Open sores or lesions in the treatment area 4. Participation in another interventional trial within the past 90 days 5. Known hypersensitivity to serum ingredients 6. Use of immunosuppressive or immunomodulatory medications 7. Any dermatological or systemic condition that may interfere with study results

Design outcomes

Primary

Measure	Time frame
1. change in Skin Pigmentation 2. change in Skin Color 3. change in Skin Hydration 4. change in TEWL 5. change in Dark Spots 6. change in Visioscan ImagingTimepoint: At t0, t30min, t14days, t28days	—

Secondary

Measure	Time frame
SGATimepoint: At t28days	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results